- Company
- Pulmican·Pulmicort prescriptions surge in asthma Tx mkt
- by Chon, Seung-Hyun Aug 5, 2024 07:50am
- The prescription market for 'budesonide' asthma drugs has expanded significantly. The drug price hike at the end of last year led to increased production and an expansion of the prescription market. The prescription market has also shown growth due to the resolution of the supply and demand imbalance made for drugs with supply and demand imbalan
- Company
- Bosulif, 2nd-generation leukemia drug available in Big 5
- by Eo, Yun-Ho Aug 5, 2024 07:50am
- The second-generation leukemia drug, 'Bosulif,' has landed in 'Big 5' general hospitals. According to industry sources, Pfizer Korea's chronic myelogenous leukemia (CML) drug, Bosulif, has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's
- Company
- Fresenius Kabi launches 2 Ntense amino acid solutions
- by Eo, Yun-Ho Aug 2, 2024 05:52am
- On the 1st, Fresenius Kabi Korea (CEO&President: Noah Park) announced the launch of its high-strength amino acid nutritional solutions ‘Ntense’ and ‘Ntense EF’ in Korea. Ntense, which stands for “Nitrogen Intensify,” is a three-chamber bag product that provides ▲nutritional treatment for critically ill patients with a high risk of
- Company
- GC·Hanmi submit IND apl. for new 'Fabry disease' drug
- by Son, Hyung-Min Aug 2, 2024 05:52am
- GC Biopharma and Hanmi Pharmaceutical announced on July 1st that they have submitted Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase 1/2 clinical trials of ‘(LA-GLA),’ a treatment for Fabry disease that they are co-developing. LA-GLA is an innovative new drug to treat Fabry disease. GC
- Company
- Next Biomedical seeks IPO…knocks on global GI mkt
- by Hwang, Byung-woo Aug 2, 2024 05:52am
- Next Biomedical will seek KOSDAQ listing in August based on its achievements in the GI field. The company has been collaborating with the global company Medtronic to expand into the endoscopic hemostatic agent market with its flagship product. Based on the revenue growth, the company plans to establish the drug as a standard-of-care in the gl
- Company
- Mounjaro bids into Korea's obesity treatment market
- by Hwang, Byung-woo Aug 2, 2024 05:51am
- Lilly Korea announced on the 1st that its GIP/GLP-1 dual-acting agent, Mounjaro (tirzepatide), has received approval from the Ministry of Food and Drug Safety (MFDS) as an adjunct for chronic weight management. Mounjaro is the first and, to date, the only (as of July 2024) GIP/GLP-1 dual receptor agonist available. It selectively binds to
- Company
- New oHCM drug 'Camzyos' is under review for reimb list
- by Eo, Yun-Ho Aug 2, 2024 05:51am
- The new drug for obstructive hypertrophic cardiomyopathy (oHCM), 'Camzyos,' has entered the last stage for reimbursement listing. Sources said that the Ministry of Health and Welfare (MOHW) ordered the National Health Insurance Service (NHIS) to initiate a drug price negotiation for Bristol Myers Squibb Korea's Camzyos (mavacamten), a tre
- Company
- VUNO knocks on the U.S. market to generate operating profit
- by Hwang, Byung-woo Aug 1, 2024 05:48am
- Medical artificial intelligence (AI) company VUNO has launched an AI-based brain quantification device in the United States market. Whether the company will use this as a stepping stone for sales expansion garners attention. VUNO's strategy is to quickly turn around by increasing the sales performance of its major product and entering the ove
- Company
- Celltrion’s Steqeyma approved in CAN…targets Stelara mkt
- by Hwang, Byung-woo Aug 1, 2024 05:48am
- On the 31st, Celltrion announced that it had received New Drug Application (NDS) approval for its Stelara biosimilar Steqeyma from Health Canada. With the approval, Celltrion may now sell Steqeyma in Canada for plaque psoriasis, psoriatic arthritis, and Crohn's disease. The Canadian approval supports the company’s plan to settle in
- Company
- Will the cardiomyopathy drug Vyndamax be reimb this time?
- by Eo, Yun-Ho Aug 1, 2024 05:48am
- The reimbursement listing process for ‘Vyndamax,’ Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), is gaining attention in Korea. According to industry sources, discussions for the reimbursement of Pfizer Korea’s Vyndamax (tafamidis 61mg) for Transthyretin amyloid&160;cardiomyopathy (ATTR-CM) have again begun.
